An observational study in Parkinson Disease and Physical Inactivity, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Karolinska Institutet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Parkinson Disease by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Karolinska Institutet.
Among the 10 studies in Parkinson Disease by Karolinska Institutet, this one is the only one that started in 2025, is one of 4 observational ones, and was the 8th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →3 of the 10 studies in Parkinson Disease by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 50 is below the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 106 across the 6 interventional studies, 292 across the 4 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
1 of the studies in Parkinson Disease by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06901869Karolinska InstitutetPhysical Activity in Persons With Parkinson's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Parkinson Disease by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parkinson's disease (PD) is a leading neurodegenerative health condition in Sweden and a public health concern. Although no cure exists, functional independence and participation in society remain top priorities, and can be achieved through targeted physical activity (PA) interventions. To date, few longitudinal cohort studies have been conducted, using PA as main outcome in therapy research, partly due to the complex nature of predicting and controlling this phenomenon. To help address this knowledge gap, the overall purpose of the future long-term (ActivPARK) study is to enhance knowledge of the evolution of PA behavior, and how it is influenced beyond the disease characteristics using a broad explanatory model, in persons with PD from a diversity of settings in Sweden with the aim of prescribing tailored and personalized interventions to enhance functioning, health, and wellbeing throughout the disease progression and recommend potential health care pathway modifications.
The investigators have just established an expert group, comprising researchers, healthcare professionals, and PD organisations (including persons with PD) and reached consensus on essential priority clinical therapy research questions on PA and methodological considerations. The next phase entails performing a multicentre feasibility/pilot study, further developing and refining the assessment battery and research questions linked to the improved explanatory model for PA and methodology, to inform the definite larger clinical cohort study.
Parkinson's disease with mild to severe severity (Hoehn \& Yahr 1-4) of all ages
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention
Feasibility of the assessment battery - length of the clinical examination and questionnaires
The pilot/feasibility study aims to evaluate feasibility of the assessment battery measured the time it takes to complete the examination and questionnaires.
Time frame: Baseline
Feasibility of the assessment battery - perception of the clinical examination
Feasibility of the assessment battery will also be evaluated through semi-structured questions regarding fatique, concentration, pain/discomfort to the participants after the clinical examination.
Time frame: Baseline
Feasibility of the assessment battery -Compliance to questionnaires sent via REDCap
Compliance will be measured with percentages of completed questionnaires in REDCap.
Time frame: Baselline
Feasibility of the assessment battery - Suitability of the primary outcome
Suitability of the accelerometers in the home environment as the primary outcome for the targeted patient group will be assessed by the percentage of participants that are able to wear the accelerometer for at least 4 days days and render valid data.
Time frame: Baseline
Physical activity levels
The ActiGraph accelerometer (GT3X+, ActiGraph, Pensacola, FL, US) will be used to measure absolute and relative time spent in sedentary behavior, low intensity physical activity (LIPA) and moderate to vigorous intensity physical activity (MVPA), by total time in bouts.
Time frame: Baseline
Physical activity - self rated
Frändin Grimby scale, ranging from 1 to 6, higher score=better.
Time frame: Baseline
Disease severity, Parkinson symptoms
Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS- UPDRS) parts 1 to 4. Higher scores = worse/more symptoms
Time frame: Baseline
Gait
Gait speed in m/s measured with the 10 meter walking test or through gait analysis.
Time frame: Baseline
Balance performance
Assessed with the Mini-BESTest. Mini-Balance Evaluation Systems Test a rating scale for dynamic balance incorporating 14 different balance and gait items that were assessed by a physical therapist on a scale from 0-2. Maximum points 28. 0-28 points with higher scores indicating better balance control
Time frame: Baseline
Anxiety and depression
Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better
Time frame: Baseline
Cognitive performance
Assessed with the Montreal Cognitive Assessment (MoCA), 0-25, higher score = better
Time frame: Baseline and 3 year follow-up
Self assessed cognitive function
Assessed with Executive function questionnaire (DEX), 20 items scored 1 to 4, max 80, more scores= worse.
Time frame: Baseline
Non-Motor Symptoms
Non-Motor Symptoms Questionnaire (NMSQ), 30 questions with yes/no answer. More yes answers = more non-motor symptoms
Time frame: Baseline
Walking ability- self assessed
WALK-12G questionnaire, 0 and 42 points, with higher scores reflecting greater perceived walking difficulties (higher=worse)
Time frame: Baseline
Freezing of gait - self-assessed
Freezing of gait questionnaire (FOGQsa), 6 questions/items, scored 1 to 5 (higher=worse)
Time frame: Baseline
Balance confidence
Activities specific balance confidence (ABC scale), 16 items which is scored 1 to 10 and then divided by 16. 0-100%, higher % = better
Time frame: Baseline
Motivation
Behavioural Regulation in Exercise Questionnaire (BREQ 4), 28 items score 1 to 7 and divided into subcomponents: Amotivation, External regulation, Introjected avoidance, Introjected approach, Identified regulation, Integrated regulation, Intrinsic regulation
Time frame: Baseline
Fatigue
Parkinson's Fatigue Scale (PFS-16), 16 items scored 1 to 5 from strongly disagree to strongly agree . more points/score= worse.
Time frame: Baseline
Disability
World health organization (WHO) disability assessment schedule (Whodas 2.0), 12 self-assessed questions (12 to 60) more points=worse
Time frame: Baseline
Self-efficacy
Self-efficacy of exercise/PA (ESES), 10 questions, scored 1-4. higher=better
Time frame: Baseline
Sleep
Scales for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP), 4 parts, A-2 questions, B-5 questions , C-1 question and D- 6 questions. Higher= worse
Time frame: Baseline
Self rated pain
Assessed with visual analog scale, VAS from 0 to 100
Time frame: Baseline
Health related quality of life
Parkinson's Disease Questionnaire (PDQ39). The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communications and bodily discomfort). The sum score is as a percentage score ranging between 0 and 100. Higher is better
Time frame: Baseline
Wellbeing
The WHO- Five Well-Being Index (WHO-5), 5 questions ranging from 0 to 5, 0-25, higher=better
Time frame: Baseline
Nutrition
Mini Nutritional Assessment, max 14. higher = better
Time frame: Baseline
Working och long-term memory
Rey-Auditory Verbal Learning Test (RAVLT), higher= better
Time frame: Baseline
Parkinson related pain
Assessed with the Kings Parkinsons Pain Scale (KPPS), max 168, higher= more pain
Time frame: Baseline
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient, provided that the recipient has an approved ethics application.
Supporting information: Statistical analysis plan
Time frame: The investigators plan to share this when applicable on OSF or similar
Access criteria: The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 21 months is below that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.